<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prochlorperazine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prochlorperazine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Prochlorperazine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10994" href="/d/html/10994.html" rel="external">see "Prochlorperazine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12734" href="/d/html/12734.html" rel="external">see "Prochlorperazine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F7290570"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Dementia:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients between 1.6 and 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was approximately 4.5% compared with a rate of approximately 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. Prochlorperazine is not approved for the treatment of patients with dementia-related psychosis.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F213829"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Compro</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868039"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ODAN-Prochlorperazine;</li>
<li>PMS-Prochlorperazine [DSC];</li>
<li>Prochlorazine</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F213858"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiemetic;</li>
<li>
                        First Generation (Typical) Antipsychotic;</li>
<li>
                        Phenothiazine Derivative</li></ul></div>
<div class="block doa drugH1Div" id="F213833"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0c941ea6-f6d2-45ba-bacd-78d5f81bec1a">Chemotherapy-induced nausea and vomiting</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chemotherapy-induced nausea and vomiting (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>IV chemotherapy agents: Low emetogenic risk (10% to 30% risk of emesis), prevention (alternative agent):</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV, Oral:</b> 5 to 10 mg once prior to chemotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18525044','lexi-content-ref-Hesketh.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18525044','lexi-content-ref-Hesketh.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Oral chemotherapy agents: Low/minimal emetogenic risk (&lt;30%), treatment and/or prevention:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral: </b>10 mg every 6 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hesketh.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hesketh.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Breakthrough nausea or vomiting, rescue therapy (adjunctive therapy) (alternative agent):</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV, Oral:</b> 5 to 10 mg every 4 to 6 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18391612']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18391612'])">Ref</a></span>); maximum: 40 mg/day.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d36d256f-8d0c-47cc-acaf-2f0f3747bed4">Migraine, moderate to severe, acute treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, moderate to severe, acute treatment (emergency setting) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Consider adjunctive use of diphenhydramine for prevention of extrapyramidal symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24875925']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24875925'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM, IV: </b>10 mg once (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24875925','lexi-content-ref-18006188','lexi-content-ref-29046364','lexi-content-ref-8639197']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24875925','lexi-content-ref-18006188','lexi-content-ref-29046364','lexi-content-ref-8639197'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Rectal:</b> 25 mg once (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8037389']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8037389'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4b16bbf2-e10d-45bd-aa5c-cfd1bb289b41">Nausea and/or vomiting, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nausea</b>
<b> and/or vomiting, acute: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May use short term (eg, up to 48 to 72 hours) for symptom relief in conditions associated with self-limiting nausea/vomiting (eg, acute vertigo, opioid withdrawal, viral gastroenteritis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Furman.2021','lexi-content-ref-Longstreth.2021a','lexi-content-ref-Sevarino.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Furman.2021','lexi-content-ref-Longstreth.2021a','lexi-content-ref-Sevarino.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 5 to 10 mg every 6 to 8 hours as needed; maximum: 40 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b> 5 to 10 mg every 3 to 4 hours as needed; maximum: 40 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>2.5 to 10 mg every 3 to 4 hours as needed; maximum: 40 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Longstreth.2021b','lexi-content-ref-21691464','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Longstreth.2021b','lexi-content-ref-21691464','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Rectal:</b></p>
<p style="text-indent:-2em;margin-left:6em;">25 mg suppository: 25 mg every 12 hours as needed.</p>
<p style="text-indent:-2em;margin-left:6em;">10 mg suppository [Canadian product]: 5 to 10 mg 3 to 4 times/day as needed.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8ad4605e-60e2-416f-ab7e-545de22137af">Nausea and vomiting, pregnancy associated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nausea and vomiting, pregnancy associated (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May be considered for adjunctive treatment when symptoms persist following initial pharmacologic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29266076']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29266076'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, IV, IM:</b> 5 to 10 mg every 6 to 8 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27986189']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27986189'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Rectal:</b> 25 mg every 12 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29266076']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29266076'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">10 mg suppository [Canadian product]: 5 to 10 mg 3 to 4 times/day.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ae1bcfa5-9563-4c6b-a1af-01aa4e2e9d9d">Postoperative nausea and vomiting, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Postoperative nausea and vomiting, prevention (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>In general, combine with one or more other prophylactic agents. Some experts consider use in patients unable to receive scopolamine patch (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Feinleib.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Feinleib.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, IM: </b>5 to 10 mg once at the end of procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9801179','lexi-content-ref-Feinleib.2021','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9801179','lexi-content-ref-Feinleib.2021','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="01cc9a62-afb1-49b1-9522-dcaaae6b89b3">Postoperative nausea and vomiting, treatment or rescue therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Postoperative nausea and vomiting, treatment or rescue therapy (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Rescue therapy should include an antiemetic from a different class than used for prophylaxis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32467512']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32467512'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, IM:</b> 5 to 10 mg once; may repeat once after 4 hours if needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9801179','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9801179','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d1f90ecd-0176-46ce-b3fa-d1e3ea7ac329">Radiation therapy–associated nausea and vomiting, rescue therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Radiation therapy–associated nausea and vomiting, rescue therapy (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Low-emetogenic risk radiation therapy (head and neck, thorax, or pelvis irradiation):</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral, IV:</b> 5 to 10 mg once if needed after each radiation treatment, then 5 to 10 mg every 6 to 8 hours if needed (maximum: 40 mg/day). Depending on symptom severity and remaining duration of therapy, patients can receive subsequent rescue therapy as needed or begin prophylactic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Minimal-emetogenic risk radiation therapy (extremities, breast irradiation):</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral, IV: </b>5 to 10 mg once if needed after each radiation treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991648"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Mild to severe impairment: No dosage adjustment necessary (minimal renal clearance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1768559','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1768559','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be dialyzed (large V<sub>d</sub>): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed (large V<sub>d</sub>): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988950"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; systemic exposure may be increased as drug undergoes hepatic metabolism.</p></div>
<div class="block doe drugH1Div" id="F213834"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Avoid for behavioral problems associated with dementia or delirium unless alternative nonpharmacologic therapies have failed and patient may harm self or others. If used, consider deprescribing attempts to assess continued need and/or lowest effective dose (Beers Criteria [AGS 2023]).</p>
<p style="text-indent:-2em;margin-left:2em;">Initiate at lower end of dosage range; increase dose slowly and cautiously. Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F213848"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12734" href="/d/html/12734.html" rel="external">see "Prochlorperazine: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Use lowest possible dose in pediatric patients to decrease incidence of extrapyramidal reactions; may consider concomitant diphenhydramine to decrease risk of dystonic adverse effects.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5f7b99ab-d14a-485c-b785-faef7923c317">Chemotherapy-induced nausea and vomiting; refractory, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chemotherapy-induced nausea and vomiting (CINV); refractory, treatment: </b>Limited data available: <b>Note:</b> Due to safety concerns, use of prochlorperazine for breakthrough or refractory CINV is not routinely recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26960036','lexi-content-ref-26884326']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26960036','lexi-content-ref-26884326'])">Ref</a></span>); however, use may be necessary in some patients.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years weighing ≥9 kg and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: 0.1 mg/kg/dose every 6 hours; maximum dose: 10 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12956617']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12956617'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">IV: 0.1 to 0.15 mg/kg/dose every 3 to 4 hours; maximum dose: 10 mg/dose; maximum daily dose: 40 mg/<b>day </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12956617']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12956617'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4e6522e8-c1db-4527-b456-1d19e61e92e3">Migraine, intractable</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, intractable:</b> Limited data available: Children ≥7 years and Adolescents: IV (as edisylate): 0.15 mg/kg as a single dose; maximum dose: 10 mg/dose; dosing based on multicenter, prospective, double-blind, randomized ketorolac comparative trial (prochlorperazine group, n=33) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14747817']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14747817'])">Ref</a></span>) and several retrospective trials (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27176905','lexi-content-ref-19150192','lexi-content-ref-32638172']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27176905','lexi-content-ref-19150192','lexi-content-ref-32638172'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="02aa7638-8c44-422a-9b32-338326e1a5a4">Nausea and vomiting, severe; treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nausea and vomiting, severe; treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Prochlorperazine has been used as an antiemetic for various presenting conditions. In most clinical situations, routine use has been replaced by alternate agents from other therapeutic classes with a more favorable safety profile (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32467512','lexi-content-ref-26960036','lexi-content-ref-26884326']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32467512','lexi-content-ref-26960036','lexi-content-ref-26884326'])">Ref</a></span>); however, prochlorperazine may be useful in severe situations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31005395']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31005395'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Oral:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Fixed dosing:</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥2 years weighing ≥9 kg and Adolescents:</p>
<p style="text-indent:-2em;margin-left:10em;">9 to 13 kg: Oral: 2.5 mg every 12 to 24 hours as needed; maximum daily dose: 7.5 mg/<b>day.</b></p>
<p style="text-indent:-2em;margin-left:10em;">&gt;13 to 18 kg: Oral: 2.5 mg every 8 to 12 hours as needed; maximum daily dose: 10 mg/<b>day.</b></p>
<p style="text-indent:-2em;margin-left:10em;">&gt;18 to 39 kg: Oral: 2.5 mg every 8 hours <b>or</b> 5 mg every 12 hours as needed; maximum daily dose: 15 mg/<b>day.</b></p>
<p style="text-indent:-2em;margin-left:10em;">&gt;39 kg: Oral: 5 to 10 mg every 6 to 8 hours; usual maximum daily dose: 40 mg/<b>day.</b></p>
<p style="text-indent:-2em;margin-left:6em;">Weight-directed dosing: Limited data available: Children ≥2 years weighing &gt;10 kg and Adolescents: Oral: 0.4 mg/kg/<b>day </b>divided every 6 to 8 hours; maximum dose: 10 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mokha.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mokha.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parenteral:</i> Prochlorperazine edisylate: Limited data available for IV route of administration: Children ≥2 years weighing ≥9 kg and Adolescents: IM (preferred), IV: 0.1 to 0.2 mg/kg/dose; maximum single dose: 10 mg/dose; frequency of administration typically every 8 to 12 hours based upon patient response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12956617','lexi-content-ref-Mokha.1','lexi-content-ref-31005395','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12956617','lexi-content-ref-Mokha.1','lexi-content-ref-31005395','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51154970"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51154971"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; systemic exposure may be increased as drug undergoes hepatic metabolism.</p></div>
<div class="block arsc drugH1Div" id="F56171251"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Anticholinergic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Phenothiazines, including prochlorperazine, may cause anticholinergic adverse effects such as <b>blurred vision</b>, <b>confusion</b>, <b>constipation</b>, dry eye,<b> urinary retention</b>, and <b>xerostomia</b>. Prochlorperazine is included in the Beers Criteria of Potentially Inappropriate Medication Use in Older Adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30693946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30693946'])">Ref</a></span>). Prochlorperazine is considered a low anticholinergic burden drug (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17101747']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17101747'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action (ie, muscarinic receptor antagonism) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29061777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29061777'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factor:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Age ≥65 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30693946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30693946'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of other anticholinergic agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30693946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30693946'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">CNS depression</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Prochlorperazine use has been associated with <b>dizziness</b>, <b>drowsiness</b>, <b>motor dysfunction (motor sensory instability)</b>, and <b>sedated state</b>. Pediatric patients are particularly susceptible to prochlorperazine-induced sedation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26884326']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26884326'])">Ref</a></span>). Prochlorperazine-related CNS depression has been associated with an increased risk of <b>falling</b> and <b>femoral neck fracture</b> in older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20623516','lexi-content-ref-19156348']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20623516','lexi-content-ref-19156348'])">Ref</a></span>). Prochlorperazine is included in the Beers Criteria of Potentially Inappropriate Medication Use in Older Adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30693946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30693946'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; typically occurs within the first 24 hours of therapy initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19156348']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19156348'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Pediatric patients and older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30693946','lexi-content-ref-20623516','lexi-content-ref-26884326']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30693946','lexi-content-ref-20623516','lexi-content-ref-26884326'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of other CNS depressants (eg, alcohol, opioids)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Extrapyramidal symptoms</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Extrapyramidal reactions </b>(EPS)<b>, </b>including <b>akathisia</b>, acute <b>dystonia</b>, drug-induced <b>parkinsonism</b>, and <b>tardive dyskinesia</b>, have occurred with the use of prochlorperazine and other dopamine receptor antagonist neuroleptic agents in adult and pediatric patients. Symptoms of EPS may be confused with other conditions, such as Reye syndrome or other encephalopathy. Acute akathisia is typically transient and resolves with drug discontinuation, but delayed akathisia may be permanent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26573884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26573884'])">Ref</a></span>). Resolution of acute dystonia occurs quickly after drug discontinuation and/or with treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17849526','lexi-content-ref-10473482']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17849526','lexi-content-ref-10473482'])">Ref</a></span>). Symptoms of drug-induced parkinsonism typically resolve within 7 weeks of drug discontinuation but may persist for 18 months or longer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25801826','lexi-content-ref-26573884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25801826','lexi-content-ref-26573884'])">Ref</a></span>). The use of dopamine receptor antagonists, such as prochlorperazine, may unmask undiagnosed idiopathic Parkinson disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27779780']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27779780'])">Ref</a></span>). Tardive dyskinesia may be irreversible; earlier drug discontinuation increases the likelihood of symptom resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26573884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26573884'])">Ref</a></span>). Tardive dyskinesia is uncommon in pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26884326']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26884326'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; due to antagonism of dopaminergic D<sub>2</sub> receptors in nigrostriatal pathways (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17849526']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17849526'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Akathisia: Rapid; usually occurs within the first 72 hours of therapy initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16490647','lexi-content-ref-10999579']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16490647','lexi-content-ref-10999579'])">Ref</a></span>); however, delayed (tardive) akathisia may occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10999579','lexi-content-ref-11239274','lexi-content-ref-26573884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10999579','lexi-content-ref-11239274','lexi-content-ref-26573884'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Acute dystonia: Rapid; usually occurs within the first 7 days after therapy initiation or a dosage increase (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17849526','lexi-content-ref-10473482','lexi-content-ref-26573884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17849526','lexi-content-ref-10473482','lexi-content-ref-26573884'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Drug-induced parkinsonism: Varied; onset may be delayed from days to weeks, with 50% to 75% of cases occurring within the first month and 90% within the first 3 months of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30027457','lexi-content-ref-26573884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30027457','lexi-content-ref-26573884'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Tardive dyskinesia: Delayed; symptoms usually occur after at least 3 months of therapy and may occur up to 3 months after therapy discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30027457','lexi-content-ref-26573884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30027457','lexi-content-ref-26573884'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors (antiemetic use in general):</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Akathisia</p>
<p style="text-indent:-2em;margin-left:8em;">- Age ≤18 years (increasing with decreasing age) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26884326','lexi-content-ref-31205194']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26884326','lexi-content-ref-31205194'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- IV administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30993680']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30993680'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Pregnancy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18071091']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18071091'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Acute dystonia</p>
<p style="text-indent:-2em;margin-left:8em;">- Age &lt;19 years (increasing with decreasing age) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10473482','lexi-content-ref-26573884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10473482','lexi-content-ref-26573884'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10473482','lexi-content-ref-26573884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10473482','lexi-content-ref-26573884'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Use of agents with high dopamine D<sub>2</sub> receptor affinity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10473482']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10473482'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- History of acute dystonia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10473482']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10473482'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Underweight or normal body weight (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31205194']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31205194'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Cocaine use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10473482']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10473482'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Pediatric:</p>
<p style="text-indent:-2em;margin-left:10em;">• Acute illnesses (eg, chickenpox, CNS infections, measles, gastroenteritis)</p>
<p style="text-indent:-2em;margin-left:10em;">• Dehydration</p>
<p style="text-indent:-2em;margin-left:6em;">• Drug-induced parkinsonism</p>
<p style="text-indent:-2em;margin-left:8em;">- Age &gt;60 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27779780']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27779780'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27779780']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27779780'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Preexisting movement disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27779780']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27779780'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Cigarette smoking (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27779780']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27779780'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Genetic variants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27779780']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27779780'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Tardive dyskinesia</p>
<p style="text-indent:-2em;margin-left:8em;">- Higher cumulative doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26573884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26573884'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Longer durations of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26573884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26573884'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Age ≥65 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31205194','lexi-content-ref-26573884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31205194','lexi-content-ref-26573884'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26573884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26573884'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26573884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26573884'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neuroleptic malignant syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroleptic Malignant Syndrome</b> (NMS), has been associated with the use of dopamine receptor antagonist neuroleptics, including prochlorperazine. Recovery generally occurs after drug discontinuation and with supportive care and treatment; however, some cases have been fatal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27423483','lexi-content-ref-Sharman.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27423483','lexi-content-ref-Sharman.2019'])">Ref</a></span>). Cases of NMS with prochlorperazine have included patients with a recent history of antipsychotic-induced NMS or use of higher prochlorperazine doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21972252','lexi-content-ref-Sharman.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21972252','lexi-content-ref-Sharman.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; idiosyncratic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8969995']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8969995'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; usually occurs within the first 2 weeks of therapy initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sharman.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sharman.2019'])">Ref</a></span>) but may also occur with the first dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21972252']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21972252'])">Ref</a></span>) or after years of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sharman.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sharman.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (suggested risk factor, but development of NMS is not dose-dependent) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27423483','lexi-content-ref-Sharman.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27423483','lexi-content-ref-Sharman.2019'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Rapid dose escalation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27423483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27423483'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of NMS with other dopamine antagonists (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21972252']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21972252'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Use of agents with high D<sub>2</sub> receptor affinity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27423483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27423483'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• IV administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27423483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27423483'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Genetic polymorphism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12555236']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12555236'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Orthostatic hypotension</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Phenothiazines, including prochlorperazine, may cause <b>orthostatic hypotension.</b> Orthostatic hypotension may increase the risk for falls in older patients; this risk may be augmented by the sedative effects of prochlorperazine.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action (ie, alpha<sub>1</sub>-adrenergic receptor blockade and anticholinergic effects) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29061777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29061777'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Age ≥65 years</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses</p>
<p style="text-indent:-2em;margin-left:6em;">• Parenteral administration</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of thiazide diuretics</p>
<p style="text-indent:-2em;margin-left:6em;">• Mitral insufficiency</p>
<p style="text-indent:-2em;margin-left:6em;">• Pheochromocytoma</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F213794"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reactions listed are based on reports for other agents in this same pharmacologic class and may not be specifically reported for prochlorperazine.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: ECG abnormality (Q wave and T wave distortions), hypotension, orthostatic hypotension, peripheral edema</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Contact dermatitis, eczema, erythema of skin, exfoliative dermatitis, pruritus, skin pigmentation, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Amenorrhea, galactorrhea not associated with childbirth, gynecomastia, hyperglycemia, hypoglycemia, menstrual disease, weight gain</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Atony of colon, cholestasis, constipation, increased appetite, intestinal obstruction, nausea, obstipation, vomiting, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Ejaculatory disorder, glycosuria, impotence, priapism, urinary retention</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Aplastic anemia, eosinophilia, hemolytic anemia, pancytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation, altered cerebrospinal proteins, anticholinergic syndrome (including cognitive impairment), brain edema, catatonia, coma, confusion, decreased cough reflex, disruption of body temperature regulation, dizziness, drowsiness, headache, insomnia, jitteriness, motor dysfunction (motor sensory instability), restlessness (motor)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Lupus-like syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, corneal deposits, deposits on or around the surface of the eye (lenticular), epithelial keratopathy, miosis, mydriasis, oculogyric crisis, retinitis pigmentosa</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Laryngeal edema, nasal congestion</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (mild; intramuscular administration)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation (Chou 2017), atrial flutter (Chou 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin photosensitivity (O'Reilly 1999)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Esophageal motility disorder (Maddalena 2004), paralytic ileus (Warnes 1967)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (in reports with antipsychotic use; risk factors may include preexisting low WBC or history of drug-induced leuko-/neutropenia; Flanagan 2008), immune thrombocytopenia (in reports with antipsychotic use; risk factors may include preexisting low WBC or history of drug-induced leuko-/neutropenia; Flanagan 2008), leukopenia (in reports with antipsychotic use; risk factors may include preexisting low WBC or history of drug-induced leuko-/neutropenia; Flanagan 2008)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Jaundice (Deller 1959)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema (Lutz 1964)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Extrapyramidal reaction (akathisia, dyskinesia, dystonia, hyperpyrexia, hyperreflexia, opisthotonos, parkinsonism, tardive dyskinesia) (Beirne 2007), falling (Caughey 2010), neuroleptic malignant syndrome (Pesola 1996), sedated state (Lau Moon Lin 2016), seizure (Bloechliger 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Femoral neck fracture (Caughey 2010)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma (including exacerbation of asthma [can be severe]) (Kuo 2022), pulmonary aspiration (Maddalena 2004)</p></div>
<div class="block coi drugH1Div" id="F213809"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Known hypersensitivity to phenothiazines; coma or presence of large amounts of CNS depressants (eg, alcohol, opioids, barbiturates); postoperative management of nausea/vomiting following pediatric surgery; use in infants and children &lt;2 years or &lt;9 kg; pediatric conditions for which dosage has not been established</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling</i>: Additional contraindications (not in the US labeling): Presence of circulatory collapse; severe cardiovascular disorders; altered state of consciousness; concomitant use of high dose hypnotics; severe depression; presence of blood dyscrasias, hepatic or renal impairment, or pheochromocytoma; suspected or established subcortical brain damage with or without hypothalamic damage</p></div>
<div class="block war drugH1Div" id="F213791"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Altered cardiac conduction: May alter cardiac conduction (life-threatening arrhythmias have occurred with therapeutic doses of phenothiazines).</p>
<p style="text-indent:-2em;margin-left:4em;">• Aspiration of vomit: Aspiration of vomit has occurred in postsurgical patients who have received prochlorperazine as an antiemetic (case reports). Although no causal relationship has been established, this possibility should be considered during post-surgical care.</p>
<p style="text-indent:-2em;margin-left:4em;">• Blood dyscrasias: Leukopenia, neutropenia, and agranulocytosis (sometimes fatal) have been reported in clinical trials and postmarketing reports with antipsychotic use; presence of risk factors (eg, preexisting low WBC or history of drug-induced leuko-/neutropenia) should prompt periodic blood count assessment. Discontinue therapy at first signs of blood dyscrasias or if absolute neutrophil count &lt;1,000/mm<sup>3</sup>.</p>
<p style="text-indent:-2em;margin-left:4em;">• Esophageal dysmotility/Aspiration: Antipsychotic use has been associated with esophageal dysmotility and aspiration; risks increase with age. Use with caution in patients at risk for aspiration pneumonia (ie, Alzheimer disease), particularly in patients &gt;75 years (Herzig 2017; Maddalena 2004).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperprolactinemia: Use associated with increased prolactin levels; clinical significance of hyperprolactinemia in patients with breast cancer or other prolactin-dependent tumors is unknown.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular effects: May cause pigmentary retinopathy, and lenticular and corneal deposits, particularly with prolonged therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Temperature regulation: Impaired core body temperature regulation may occur; caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with severe cardiovascular disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI motility: Use with caution in patients with decreased GI motility (eg, paralytic ileus) as anticholinergic effects may exacerbate underlying condition.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ophthalmic conditions: Use with caution in patients with certain ophthalmic conditions (eg, visual problems) as anticholinergic effects may exacerbate underlying condition.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Reye syndrome: Avoid use in patients with signs/symptoms suggestive of Reye syndrome.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorder: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.</p>
<p style="text-indent:-2em;margin-left:4em;">• Urinary tract conditions: Use with caution in patients with urinary retention or benign prostatic hyperplasia as anticholinergic effects may exacerbate underlying condition.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sodium sulfite: Some dosage forms may contain sodium sulfite.</p></div>
<div class="block foc drugH1Div" id="F213803"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as edisylate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/2 mL (2 mL); 50 mg/10 mL (10 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suppository, Rectal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Compro: 25 mg (12 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg (1 ea, 12 ea, 1000 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as maleate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg</p></div>
<div class="block geq drugH1Div" id="F213787"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F213812"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Prochlorperazine Edisylate Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/2 mL (per mL): $2.75 - $11.10</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suppository</b> (Compro Rectal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $12.58</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suppository</b> (Prochlorperazine Rectal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $12.26</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Prochlorperazine Maleate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $0.59 - $0.60</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.71 - $0.90</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868040"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg/mL ([DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suppository, Rectal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg (10 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as maleate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg</p></div>
<div class="block adm drugH1Div" id="F213806"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> Inject by deep IM into outer quadrant of buttocks. Avoid skin contact with injection solution, contact dermatitis has occurred. Do not administer SUBQ; may cause local irritation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> May be administered diluted or undiluted by slow IV push or by IV infusion at a maximum rate of 5 mg/minute. To reduce the risk of hypotension, patients receiving IV prochlorperazine must remain lying down and be observed for at least 30 minutes following administration. Avoid skin contact with injection solution, contact dermatitis has occurred. Do not administer SUBQ; may cause local irritation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rectal:</b> Do not remove from wrapper until ready to use.</p></div>
<div class="block admp drugH1Div" id="F52613681"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer with food or water.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: <b>Note:</b> Avoid skin contact with injection solution; contact dermatitis has occurred; do not administer subcutaneously; may cause local irritation.</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Preferred route; inject by deep IM injection into the outer quadrant of buttocks.</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Route typically avoided; if necessary, may be administered by slow IV push by direct IV injection at a rate not to exceed 5 mg/minute. To reduce the risk of hypotension, patients receiving IV prochlorperazine must remain lying down and be observed for at least 30 minutes following administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Rectal: Do not remove from wrapper until ready for use. <b>Note:</b> Appropriate dosage form for rectal administration in pediatric patients is no longer available in the US.</p></div>
<div class="block use drugH1Div" id="F213805"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Nausea and/or vomiting, acute: </b>Management of severe nausea and vomiting.</p></div>
<div class="block off-label drugH1Div" id="F51670635"><span class="drugH1">Use: Off-Label: Adult</span><p>Chemotherapy-induced nausea and vomiting; Migraine, moderate to severe, acute treatment (emergency setting); Postoperative nausea and/or vomiting, prevention; Postoperative nausea and/or vomiting, treatment or rescue therapy; Pregnancy-associated nausea and vomiting; Radiation therapy–associated nausea and vomiting, rescue therapy</p></div>
<div class="block mst drugH1Div" id="F213867"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Prochlorperazine may be confused with chlorproMAZINE.</p>
<p style="text-indent:-2em;margin-left:4em;">Compazine may be confused with Copaxone, Coumadin.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-risk medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Antipsychotics are identified in the Beers Criteria as potentially inappropriate medications to be avoided in patients ≥65 years of age due to an increased risk of stroke and a greater rate of cognitive decline and mortality in patients with dementia. Evidence also suggests there may be an increased risk of mortality with use independent of dementia. Avoid antipsychotics for behavioral problems associated with dementia or delirium unless alternative nonpharmacologic therapies have failed and patient may harm self or others. In addition, antipsychotics should be used with caution in older adults due to their potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults. Prochlorperazine is identified in the Beers Criteria as a potentially inappropriate medication in patients ≥65 years of age due to its strong anticholinergic properties resulting in increased risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity. Use of antipsychotics may be appropriate for labeled indications including schizophrenia, bipolar disorder, Parkinson disease psychosis, adjunctive therapy in major depressive disorder, or for short-term use as an antiemetic (Beers Criteria [AGS 2023]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pediatric patients: High-risk medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">KIDs List: Dopamine antagonists, when used in pediatric patients &lt;18 years of age, are identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list; use should be avoided in infants and used with caution in children and adolescents due to risk of acute dystonia (dyskinesia), and with intravenous administration an increased risk of respiratory depression, extravasation, and death (strong recommendation; moderate quality of evidence) (PPA [Meyers 2020]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">CPZ (occasional abbreviation for Compazine) is an error-prone abbreviation (mistaken as chlorpromazine).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299946"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F213796"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents With Seizure Threshold Lowering Potential: May enhance the adverse/toxic effect of Prochlorperazine. Specifically, the risk of seizures may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifampridine: Agents With Seizure Threshold Lowering Potential may enhance the neuroexcitatory and/or seizure-potentiating effect of Amifampridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk of neuroleptic malignant syndrome or increased QTc interval may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Amisulpride (Oral). Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May decrease the absorption of Antipsychotic Agents (Phenothiazines).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anti-Parkinson Agents (Dopamine Agonist): May diminish the therapeutic effect of Antipsychotic Agents (First Generation [Typical]). Antipsychotic Agents (First Generation [Typical]) may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). Management: Avoid concomitant therapy if possible. If antipsychotic use is necessary, consider using atypical antipsychotics such as clozapine, quetiapine, or ziprasidone at lower initial doses, or a non-dopamine antagonist (eg, pimavanserin).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole Lauroxil. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asenapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Asenapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Benperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers: Antipsychotic Agents (Phenothiazines) may enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Brexpiprazole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabergoline: May diminish the therapeutic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Cariprazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ChlorproMAZINE: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ChlorproMAZINE. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Anticholinergic Agents may enhance the anticholinergic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clothiapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Clothiapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferoxamine: May enhance the adverse/toxic effect of Prochlorperazine. Specifically, prolonged loss of consciousness has been reported. Management: Consider alternatives to prochlorperazine in patients receiving deferoxamine, due to a risk of temporary impairment of consciousness (potentially lasting for days) with the combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deutetrabenazine: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for akathisia, parkinsonism, or neuroleptic malignant syndrome may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dofetilide: Prochlorperazine may increase the serum concentration of Dofetilide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Donepezil: May enhance the neurotoxic (central) effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flupentixol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Flupentixol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FluPHENAZine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of FluPHENAZine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Galantamine: May enhance the neurotoxic (central) effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: Antipsychotic Agents may diminish the therapeutic effect of Guanethidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Haloperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Huperzine A: May enhance the neurotoxic (central) effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iloperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iloperidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: May enhance the neurotoxic effect of Antipsychotic Agents. Lithium may decrease the serum concentration of Antipsychotic Agents. Specifically noted with chlorpromazine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loxapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Loxapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lumateperone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lurasidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mequitazine: Antipsychotic Agents may enhance the arrhythmogenic effect of Mequitazine.  Management: Consider alternatives to one of these agents when possible.  While this combination is not specifically contraindicated, mequitazine labeling describes this combination as discouraged.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for extrapyramidal symptoms and excessive sedation may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molindone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Molindone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of OLANZapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paliperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Paliperidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Periciazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Periciazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perphenazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Perphenazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Pimozide. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pipamperone [INT]: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Pipamperone [INT]. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: Antipsychotic Agents may diminish the therapeutic effect of Piribedil. Piribedil may diminish the therapeutic effect of Antipsychotic Agents.  Management: Use of piribedil with antiemetic neuroleptics is contraindicated, and use with antipsychotic neuroleptics, except for clozapine, is not recommended.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Polyethylene Glycol-Electrolyte Solution. Specifically, the risk of seizure may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.  Management:  Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Promazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of QUEtiapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: Antipsychotic Agents may diminish the therapeutic effect of Quinagolide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of RisperiDONE. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents.  Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: Antipsychotic Agents (Phenothiazines) may enhance the arrhythmogenic effect of Saquinavir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk): May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonergic agents may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sertindole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure or loss of consciousness may be increased in patients with significant sodium phosphate-induced fluid or electrolyte abnormalities. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulpiride: Antipsychotic Agents may enhance the adverse/toxic effect of Sulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for NMS and extrapyramidal symptoms may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiopental: Antipsychotic Agents (Phenothiazines) may enhance the adverse/toxic effect of Thiopental. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Thioridazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiothixene: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Thiothixene. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trifluoperazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Trifluoperazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ziprasidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Ziprasidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuclopenthixol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Zuclopenthixol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49321697"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Use may interfere with pregnancy tests, causing false positive results.</p></div>
<div class="block pri drugH1Div" id="F213813"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Jaundice or hyper- or hyporeflexia have been reported in newborn infants following maternal use of phenothiazines. Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization.</p>
<p style="text-indent:0em;margin-top:2em;">The use of prochlorperazine may be considered for adjunctive treatment of nausea and vomiting in pregnant patients when symptoms persist following initial pharmacologic therapy (ACOG 2018).</p></div>
<div class="block brc drugH1Div" id="F1181961"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if prochlorperazine is present in breast milk. Other phenothiazines are excreted in breast milk.</p></div>
<div class="block dic drugH1Div" id="F213814"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Increase dietary intake of riboflavin; should be administered with food or water. Rectal suppositories may contain coconut and palm oil.</p></div>
<div class="block mop drugH1Div" id="F213801"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Mental status and alertness; vital signs (as clinically indicated); weight, height, BMI, waist circumference (baseline; at every visit for the first 6 months; quarterly with stable antipsychotic dose); CBC (as clinically indicated; monitor frequently during the first few months of therapy in patients with preexisting low WBC or history of drug-induced leukopenia/neutropenia); electrolytes and liver function (annually and as clinically indicated); fasting plasma glucose level/HbA<sub>1c</sub> (baseline, then yearly; in patients with diabetes risk factors or if gaining weight repeat 4 months after starting antipsychotic, then yearly); lipid panel (baseline; repeat every 2 years if LDL level is normal; repeat every 6 months if LDL level is &gt;130 mg/dL); changes in menstruation, libido, development of galactorrhea, erectile and ejaculatory function (at each visit for the first 12 weeks after the antipsychotic is initiated or until the dose is stable, then yearly); abnormal involuntary movements or parkinsonian signs (baseline; repeat weekly until dose stabilized for at least 2 weeks after introduction and for 2 weeks after any significant dose increase); tardive dyskinesia (every 6 months; high-risk patients every 3 months); visual changes (inquire yearly); ocular examination (yearly in patients &gt;40 years; every 2 years in younger patients) (ADA 2004; Lehman 2004; Marder 2004); fall risk (baseline and periodically during treatment in patients with diseases or on medications that may also increase fall risk).</p></div>
<div class="block pha drugH1Div" id="F213790"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Prochlorperazine is a piperazine phenothiazine antipsychotic which blocks postsynaptic mesolimbic dopaminergic D<sub>1</sub> and D<sub>2</sub> receptors in the brain, including the chemoreceptor trigger zone; exhibits a strong alpha-adrenergic and anticholinergic blocking effect and depresses the release of hypothalamic and hypophyseal hormones; believed to depress the reticular activating system, thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone and emesis</p></div>
<div class="block phk drugH1Div" id="F213808"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Oral: 30 to 40 minutes; IM: 10 to 20 minutes; Rectal: ~60 minutes </p>
<p style="text-indent:-2em;margin-left:4em;">Peak antiemetic effect: IV: 30 to 60 minutes</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: Rectal: 3 to 12 hours; IM, Oral: 3 to 4 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: 1400 to 1548 L (Taylor 1987)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Primarily hepatic; N-desmethyl prochlorperazine (major active metabolite) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: Oral: 12.5% (Isah 1991)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Oral: 6 to 10 hours (single dose), 14 to 22 hours (repeated dosing) (Isah 1991); IV: 6 to 10 hours (Isah 1991; Taylor 1987)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Mainly in feces</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038782"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Buccastem | Stemetil</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Amcal prochlorperazine | Apo Prochlorperazine | Blooms the chemist prochlorperazine | Chemists own procalm | Compazine | Nausetil | Nausrelief | Ph prochloroperzine | Pharmacor Prozine | Pharmacy care prochlorperazine | Priceline pharmacy prochlorperazine | Procalm | Prochlorperazine | Prochlorperazine an | Prochlorperazine GA | Prochlorperazne PS | Stemetil | Stemzine | Terry white chemists prochlorperazine</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Ametil | Avotil | Emitab | Gemetil | Melatil | Promat | Promtil | Pronotil | Stemetil | Temtil | Vergon | Vertigan</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Prochlorperazin</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Emetiral | Stemetil</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Depafen | Klometil | Stemetil</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Buccastem | Buccastem m | Prochlorperaz | Prochlorperazine | Prochlorperazine maleate kent pharm | Proziere | Stemetil</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Dhaperazine | Metil | Metil b | Nautisol | Pcp | Pemazil | Peratil | Prochlor | Prochlorperazine | Properzine | Protil | Seratil | Stemetil</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Stemetil</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Buccastem | Prochlorperazine | Stemetil</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Bukatel | Comptil | Emestop MD | Emidoxyn | Emikind | Ingametil | Mentil | Nausetil | Prochlor | Prochlorperazine | Prometil | Setil | Stemetil | Stevom | Stimat | Vestil | Vometil | Westel</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Furametil</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Stemetil</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Nibromin a | Normalmin | Novamin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Buccastem | Stemetil</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Prochlorperazin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Emetiral | Prochlorperazin</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Cametil | Dhaperazine | Liconate | Maprotil | Nautisol | Parazine | Pcp | Primetil | Prochlor | Prochlorperazine | Prometil | Protazine | Stemetil</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Stemetil</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Compro | Stemetil</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Antinaus | Buccastem | Nausafix | Prochlorperazine IPCA | Stemetil</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Stemetil</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Damotil | Emetil | Emitin | Procotil | Stabil | Stemetil</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Chloropernazinum | Stemetil</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Compazine | Compro | Prochlorperaz maleate | Prochlorperazine</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Nautisol</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Emetiral</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Chlozepid</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Stemetil</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Cametil | Dhaperazine | Maprotil | Pcp | Peratil | Prochlor | Prochlorperazine | Stemetil</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Prochlorperazin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Novamin | Peratil | Prochlorperazine | Proclozine | Prometil | Properan | Stabil | Stemetil</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Daolin | Lotamin | Mormal | Novamin | Novomit | Proazine | Prochlorperazine | Prochlozine | Promin | Promine | Roumin | Volimin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Mitil | Prochlorperazine | Scripto-metic | Stemetil</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Stemetil</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Stemetil</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-30693946">
<a name="30693946"></a>2019 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2019;67(4):674-694. doi:10.1111/jgs.15767<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/30693946/pubmed" id="30693946" target="_blank">30693946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APA.2016">
<a name="APA.2016"></a>American Psychiatric Association. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. 2016. Approved December 13, 2015. https://psychiatryonline.org/doi/pdf/10.1176/appi.books.9780890426807
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319. doi:10.1067/mpd.2001.116281<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29266076">
<a name="29266076"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 189: Nausea and vomiting of pregnancy. <i>Obstet Gynecol</i>. 2018;131(1):e15-e30. doi:10.1097/AOG.0000000000002456.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/29266076/pubmed" id="29266076" target="_blank">29266076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15003083">
<a name="15003083"></a>American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. <i>J Clin Psychiatry</i>. 2004;65(2):267-272. doi:10.4088/jcp.v65n0219<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/15003083/pubmed" id="15003083" target="_blank">15003083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24713617">
<a name="24713617"></a>Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder, and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. <i>J Psychopharmacol. </i>2014;28(5):403-439. doi:10.1177/0269881114525674<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/24713617/pubmed" id="24713617" target="_blank">24713617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35900161">
<a name="35900161"></a>Bandelow B, Allgulander C, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - version 3. Part I: anxiety disorders. <i>World J Biol Psychiatry</i>. 2023;24(2):79-117. doi:10.1080/15622975.2022.2086295<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/35900161/pubmed" id="35900161" target="_blank">35900161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17849526">
<a name="17849526"></a>Beirne M, Fenton J. Acute dystonic reaction secondary to prochlorperazine use in the treatment of hyperemesis gravidarum. <i>Ir J Med Sci</i>. 2007;176(1):53-54. doi:10.1007/s11845-007-0005-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/17849526/pubmed" id="17849526" target="_blank">17849526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26242478">
<a name="26242478"></a>Bloechliger M, Rüegg S, Jick SS, Meier CR, Bodmer M. Antipsychotic drug use and the risk of seizures: follow-up study with a nested case-control analysis. <i>CNS Drugs</i>. 2015;29(7):591-603. doi:10.1007/s40263-015-0262-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/26242478/pubmed" id="26242478" target="_blank">26242478</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16490647">
<a name="16490647"></a>Braude D, Soliz T, Crandall C, Hendey G, Andrews J, Weichenthal L. Antiemetics in the ED: a randomized controlled trial comparing 3 common agents. <i>Am J Emerg Med</i>. 2006;24(2):177-182. doi:10.1016/j.ajem.2005.08.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/16490647/pubmed" id="16490647" target="_blank">16490647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14747817">
<a name="14747817"></a>Brousseau DC, Duffy SJ, Anderson AC, Linakis JG. Treatment of pediatric migraine headaches: a randomized, double-blind trial of prochlorperazine versus ketorolac. <i>Ann Emerg Med</i>. 2004;43(2):256-262. doi:10.1016/s0196-0644(03)00716-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/14747817/pubmed" id="14747817" target="_blank">14747817</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27986189">
<a name="27986189"></a>Campbell K, Rowe H, Azzam H, Lane CA. The management of nausea and vomiting of pregnancy. <i>J Obstet Gynaecol Can</i>. 2016;38(12):1127-1137. doi:10.1016/j.jogc.2016.08.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/27986189/pubmed" id="27986189" target="_blank">27986189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17101747">
<a name="17101747"></a>Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. <i>J Clin Pharmacol</i>. 2006;46(12):1481-1486. doi:10.1177/0091270006292126<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/17101747/pubmed" id="17101747" target="_blank">17101747</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20623516">
<a name="20623516"></a>Caughey GE, Roughead EE, Pratt N, Shakib S, Vitry AI, Gilbert AL. Increased risk of hip fracture in the elderly associated with prochlorperazine: is a prescribing cascade contributing? <i>Pharmacoepidemiol Drug Saf</i>. 2010;19(9):977-982. doi:10.1002/pds.2009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/20623516/pubmed" id="20623516" target="_blank">20623516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9801179">
<a name="9801179"></a>Chen JJ, Frame DG, White TJ. Efficacy of ondansetron and prochlorperazine for the prevention of postoperative nausea and vomiting after total hip replacement or total knee replacement procedures: a randomized, double-blind, comparative trial. <i>Arch Intern Med</i>. 1998;158(19):2124-2128. doi:10.1001/archinte.158.19.2124<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/9801179/pubmed" id="9801179" target="_blank">9801179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27855291">
<a name="27855291"></a>Chou RH, Lo LW, Liou YJ, et al. Antipsychotic treatment is associated with risk of atrial fibrillation: A nationwide nested case-control study. <i>Int J Cardiol</i>. 2017;227:134-140. doi:10.1016/j.ijcard.2016.11.185<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/27855291/pubmed" id="27855291" target="_blank">27855291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Compazine.2013.12">
<a name="Compazine.2013.12"></a>Compazine (prochlorperazine) [prescribing information]. Charlottesville, VA: PBM Pharmaceuticals; December 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CompazineSupp.2013.04">
<a name="CompazineSupp.2013.04"></a>Compazine (prochlorperazine suppositories) [prescribing information]. Charlottesville, VA: PBM Pharmaceuticals; April 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ComproSupp.2016.11">
<a name="ComproSupp.2016.11"></a>Compro suppositories (prochlorperazine) [prescribing information]. Minneapolis, MN: Perrigo; November 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20788784">
<a name="20788784"></a>Deller DJ, Brodziak IA, Phillips AD. Jaundice during prochlorperazine therapy. <i>Br Med J</i>. 1959;2(5142):93. doi:10.1136/bmj.2.5142.93<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/20788784/pubmed" id="20788784" target="_blank">20788784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12956617">
<a name="12956617"></a>Dupuis LL, Nathan PC. Options for the Prevention and Management of Acute Chemotherapy-Induced Nausea and Vomiting in Children. <i>Paediatr Drugs.</i> 2003;5(9):597-613. doi:10.2165/00148581-200305090-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/12956617/pubmed" id="12956617" target="_blank">12956617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1862161">
<a name="1862161"></a>Earle-Boyer EA, Serper MR, Davidson M, Harvey PD. Continuous performance tests in schizophrenic patients: stimulus and medication effects on performance. <i>Psychiatry Res</i>. 1991;37(1):47-56. doi:10.1016/0165-1781(91)90105-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/1862161/pubmed" id="1862161" target="_blank">1862161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19164494">
<a name="19164494"></a>Elie D, Poirier M, Chianetta J, Durand M, Grégoire C, Grignon S. Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder. <i>J Psychopharmacol</i>. 2010;24(7):1037-1044. doi:10.1177/0269881108100777<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/19164494/pubmed" id="19164494" target="_blank">19164494</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25801826">
<a name="25801826"></a>Erro R, Bhatia KP, Tinazzi M. Parkinsonism following neuroleptic exposure: A double-hit hypothesis? <i>Mov Disord</i>. 2015;30(6):780-785. doi:10.1002/mds.26209<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/25801826/pubmed" id="25801826" target="_blank">25801826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Feinleib.2021">
<a name="Feinleib.2021"></a>Feinleib J, Kwan LH, Yamani A. Postoperative nausea and vomiting. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 5, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30993680">
<a name="30993680"></a>Fernando T, Lumanauw DD, Youn S, et al. Buccally absorbed vs intravenous prochlorperazine for treatment of migraines headaches. <i>Acta Neurol Scand</i>. 2019;140(1):72-77. doi:10.1111/ane.13104<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/30993680/pubmed" id="30993680" target="_blank">30993680</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18098216">
<a name="18098216"></a>Flanagan RJ, Dunk L. Haematological toxicity of drugs used in psychiatry. <i>Hum Psychopharmacol</i>. 2008;23(suppl 1):27-41. doi:10.1002/hup.917<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/18098216/pubmed" id="18098216" target="_blank">18098216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26960036">
<a name="26960036"></a>Flank J, Robinson PD, Holdsworth M, et al. Guideline for the treatment of breakthrough and the prevention of refractory chemotherapy-induced nausea and vomiting in children with cancer. <i>Pediatr Blood Cancer</i>. 2016;63(7):1144-1151. doi:10.1002/pbc.25955<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/26960036/pubmed" id="26960036" target="_blank">26960036</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18006188">
<a name="18006188"></a>Friedman BW, Esses D, Solorzano C, et al. A randomized controlled trial of prochlorperazine versus metoclopramide for treatment of acute migraine. <i>Ann Emerg Med</i>. 2008;52(4):399-406. doi:10.1016/j.annemergmed.2007.09.027.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/18006188/pubmed" id="18006188" target="_blank">18006188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29046364">
<a name="29046364"></a>Friedman BW, Irizarry E, Solorzano C, et al. Randomized study of IV prochlorperazine plus diphenhydramine vs IV hydromorphone for migraine. <i>Neurology</i>. 2017;89(20):2075-2082. doi:10.1212/WNL.0000000000004642<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/29046364/pubmed" id="29046364" target="_blank">29046364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Furman.2021">
<a name="Furman.2021"></a>Furman JM, Barton JJS. Treatment of vertigo. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 28, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32467512">
<a name="32467512"></a>Gan TJ, Belani KG, Bergese S, et al. Fourth consensus guidelines for the management of postoperative nausea and vomiting. <i>Anesth Analg.</i> 2020;131(2):411-448. doi:10.1213/ANE.0000000000004833<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/32467512/pubmed" id="32467512" target="_blank">32467512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12476402">
<a name="12476402"></a>Golembiewski JA, O'Brien D. A systematic approach to the management of postoperative nausea and vomiting.<i> J Perianesth Nurs.</i> 2002;17(6):364-376. doi:10.1053/jpan.2002.36596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/12476402/pubmed" id="12476402" target="_blank">12476402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12904095">
<a name="12904095"></a>Hall RL, Smith AG, Edwards JG. Haematological safety of antipsychotic drugs. <i>Expert Opin Drug Saf</i>. 2003;2(4):395-399. doi:10.1517/14740338.2.4.395<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/12904095/pubmed" id="12904095" target="_blank">12904095</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22834451">
<a name="22834451"></a>Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. <i>World J Biol Psychiatry</i>. 2012;13(5):318-378. doi:10.3109/15622975.2012.696143<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/22834451/pubmed" id="22834451" target="_blank">22834451</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29095482">
<a name="29095482"></a>Herzig SJ, LaSalvia MT, Naidus E, et al. Antipsychotics and the risk of aspiration pneumonia in individuals hospitalized for nonpsychiatric conditions: a cohort study. <i>J Am Geriatr Soc</i>. 2017;65(12):2580-2586. doi:10.1111/jgs.15066.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/29095482/pubmed" id="29095482" target="_blank">29095482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18525044">
<a name="18525044"></a>Hesketh PJ. Chemotherapy-induced nausea and vomiting. <i>N Engl J Med</i>. 2008;358(23):2482-2494. doi:10.1056/NEJMra0706547<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/18525044/pubmed" id="18525044" target="_blank">18525044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hesketh.2021">
<a name="Hesketh.2021"></a>Hesketh PJ. Prevention of chemotherapy-induced nausea and vomiting in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 22, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32658626">
<a name="32658626"></a>Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. <i>J Clin Oncol.</i> 2020;38(24):2782-2797. doi:10.1200/JCO.20.01296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/32658626/pubmed" id="32658626" target="_blank">32658626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27888683">
<a name="27888683"></a>Husa AP, Moilanen J, Murray GK, et al. Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort. <i>Psychiatry Res</i>. 2017;247:130-138. doi:10.1016/j.psychres.2016.10.085<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/27888683/pubmed" id="27888683" target="_blank">27888683</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25034761">
<a name="25034761"></a>Husa AP, Rannikko I, Moilanen J, et al. Lifetime use of antipsychotic medication and its relation to change of verbal learning and memory in midlife schizophrenia - An observational 9-year follow-up study. <i>Schizophr Res</i>. 2014;158(1-3):134-141. doi:10.1016/j.schres.2014.06.035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/25034761/pubmed" id="25034761" target="_blank">25034761</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278. doi:10.1542/peds.99.2.268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1768559">
<a name="1768559"></a>Isah AO, Rawlins MD, Bateman DN. Clinical pharmacology of prochlorperazine in healthy young males. <i>Br J Clin Pharmacol.</i> 1991;32(6):677-684.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/1768559/pubmed" id="1768559" target="_blank">1768559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8037389">
<a name="8037389"></a>Jones EB, Gonzalez ER, Boggs JG, Grillo JA, Elswick RK Jr. Safety and efficacy of rectal prochlorperazine for the treatment of migraine in the emergency department. <i>Ann Emerg Med</i>. 1994;24(2):237-241. doi:10.1016/s0196-0644(94)70135-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/8037389/pubmed" id="8037389" target="_blank">8037389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8639197">
<a name="8639197"></a>Jones J, Pack S, Chun E. Intramuscular prochlorperazine versus metoclopramide as single-agent therapy for the treatment of acute migraine headache. <i>Am J Emerg Med</i>. 1996;14(3):262-264. doi:10.1016/S0735-6757(96)90171-0.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/8639197/pubmed" id="8639197" target="_blank">8639197</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20045576">
<a name="20045576"></a>Kostic MA, Gutierrez FJ, Rieg TS, Moore TS, Gendron RT. A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department. <i>Ann Emerg Med</i>. 2010;56(1):1-6. doi:10.1016/j.annemergmed.2009.11.020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/20045576/pubmed" id="20045576" target="_blank">20045576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35287638">
<a name="35287638"></a>Kuo CW, Yang SC, Shih YF, Liao XM, Lin SH. Typical antipsychotics is associated with increased risk of severe exacerbation in asthma patients: a nationwide population-based cohort study. <i>BMC Pulm Med</i>. 2022;22(1):85. doi: 10.1186/s12890-022-01883-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/35287638/pubmed" id="35287638" target="_blank">35287638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26884326">
<a name="26884326"></a>Lau Moon Lin M, Robinson PD, Flank J, Sung L, Dupuis LL. The safety of prochlorperazine in children: a systematic review and meta-analysis. <i>Drug Saf</i>. 2016;39(6):509-516. doi:10.1007/s40264-016-0398-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/26884326/pubmed" id="26884326" target="_blank">26884326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15000267">
<a name="15000267"></a>Lehman AF, Lieberman JA, Dixon LB, et al; American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. <i>Am J Psychiatry</i>. 2004;161(2)(suppl):1-56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/15000267/pubmed" id="15000267" target="_blank">15000267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31643452">
<a name="31643452"></a>LiverTox: Clinical and research information on drug-induced liver injury [internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Prochlorperazine. Updated July 1, 2020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/31643452/pubmed" id="31643452" target="_blank">31643452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-466547">
<a name="466547"></a>Loeser EA, Bennett G, Stanley TH, Machin R. Comparison of droperidol, haloperidol and prochlorperazine as postoperative anti-emetics. <i>Can Anaesth Soc J.</i> 1979;26(2):125-127. doi:10.1007/BF03013781<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/466547/pubmed" id="466547" target="_blank">466547</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18391612">
<a name="18391612"></a>Lohr L. Chemotherapy-induced nausea and vomiting. <i>Cancer J</i>. 2008;14(2):85-93. doi:10.1097/PPO.0b013e31816a0f07<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/18391612/pubmed" id="18391612" target="_blank">18391612</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Longstreth.2021a">
<a name="Longstreth.2021a"></a>Longstreth GF. Approach to the adult with nausea and vomiting. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 17, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Longstreth.2021b">
<a name="Longstreth.2021b"></a>Longstreth GF, Hesketh PJ. Characteristics of antiemetic drugs. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 17, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14178695">
<a name="14178695"></a>Lutz EG, Rotov MD. Angioneurotic edema of the tongue with phenothiazine administration: Report of two cases. <i>Dis Nerv Syst</i>. 1964;25:419-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/14178695/pubmed" id="14178695" target="_blank">14178695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15138897">
<a name="15138897"></a>Maddalena AS, Fox M, Hofmann M, Hock C. Esophageal dysfunction on psychotropic medication. A case report and literature review. <i>Pharmacopsychiatry</i>. 2004;37(3):134-138. doi:10.1055/s-2004-818993<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/15138897/pubmed" id="15138897" target="_blank">15138897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15285957">
<a name="15285957"></a>Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. <i>Am J Psychiatry</i>. 2004;161(8):1334-1349. doi:10.1176/appi.ajp.161.8.1334<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/15285957/pubmed" id="15285957" target="_blank">15285957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23972700">
<a name="23972700"></a>McClellan J, Stock S; American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. <i>J Am Acad Child Adolesc Psychiatry</i>. 2013;52(9):976-990. doi:10.1016/j.jaac.2013.02.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/23972700/pubmed" id="23972700" target="_blank">23972700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32265601">
<a name="32265601"></a>Meyers RS, Thackray J, Matson KL, et al. <i>K</i>ey Potentially <i>I</i>nappropriate <i>D</i>rugs in Pediatrics: The KIDs List. <i>J Pediatr Pharmacol Ther</i>. 2020;25(3):175-191. doi:10.5863/1551-6776-25.3.175<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/32265601/pubmed" id="32265601" target="_blank">32265601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12555236">
<a name="12555236"></a>Mihara K, Kondo T, Suzuki A, et al. Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome. <i>Am J Med Genet B Neuropsychiatr Genet</i>. 2003;117B(1):57-60. doi:10.1002/ajmg.b.10025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/12555236/pubmed" id="12555236" target="_blank">12555236</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19371522">
<a name="19371522"></a>Miller MA, Levsky ME, Enslow W, Rosin A. Randomized evaluation of octreotide vs prochlorperazine for ED treatment of migraine headache. <i>Am J Emerg Med</i>. 2009;27(2):160-164. doi:10.1016/j.ajem.2008.01.015.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/19371522/pubmed" id="19371522" target="_blank">19371522</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mokha.1">
<a name="Mokha.1"></a>Mokha J. Vomiting and nausea. In: Wyllie R, Hyams JS, Kay M, eds. <i>Pediatric Gastrointestinal and Liver Disease</i>. 6th ed. Elsevier; 2020:chap 8.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31205194">
<a name="31205194"></a>Musco S, Ruekert L, Myers J, Anderson D, Welling M, Cunningham EA. Characteristics of patients experiencing extrapyramidal symptoms or other movement disorders related to dopamine receptor blocking agent therapy. <i>J Clin Psychopharmacol</i>. 2019;39(4):336-343. doi:10.1097/JCP.0000000000001061<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/31205194/pubmed" id="31205194" target="_blank">31205194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21972252">
<a name="21972252"></a>Musselman ME, Browning LA, Parker D Jr, Saely S. Neuroleptic malignant syndrome associated with the use of prochlorperazine in a patient with a recent history of antipsychotic-induced neuroleptic malignant syndrome. <i>Ann Pharmacother</i>. 2011;45(11):e61. doi:10.1345/aph.1Q325<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/21972252/pubmed" id="21972252" target="_blank">21972252</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10999579">
<a name="10999579"></a>Olsen JC, Keng JA, Clark JA. Frequency of adverse reactions to prochlorperazine in the ED. <i>Am J Emerg Med</i>. 2000;18(5):609-611. doi:10.1053/ajem.2000.9283<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/10999579/pubmed" id="10999579" target="_blank">10999579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10233667">
<a name="10233667"></a>O'Reilly FM, McKenna D, Murphy GM. Is monochromatic irradiation testing useful in the differentiation of drug-induced photosensitivity from chronic actinic dermatitis? <i>Clin Exp Dermatol</i>. 1999;24(2):118-121. doi:10.1046/j.1365-2230.1999.00430.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/10233667/pubmed" id="10233667" target="_blank">10233667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24875925">
<a name="24875925"></a>Orr SL, Aubé M, Becker WJ, et al. Canadian Headache Society systematic review and recommendations on the treatment of migraine pain in emergency settings. <i>Cephalalgia</i>. 2015;35(3):271-284. doi:10.1177/0333102414535997<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/24875925/pubmed" id="24875925" target="_blank">24875925</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27300483">
<a name="27300483"></a>Orr SL, Friedman BW, Christie S, et al. Management of adults with acute migraine in the emergency department: the American Headache Society evidence assessment of parenteral pharmacotherapies. <i>Headache</i>. 2016;56(6):911-940. doi:10.1111/head.12835.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/27300483/pubmed" id="27300483" target="_blank">27300483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31005395">
<a name="31005395"></a>Ouellette L, Judge B, Zamarripa A, McFadden P, Jones J. Safety and effectiveness of intravenous prochlorperazine for intractable vomiting in children with gastroenteritis. <i>Am J Emerg Med</i>. 2019;37(10):1982-1983. doi:10.1016/j.ajem.2019.04.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/31005395/pubmed" id="31005395" target="_blank">31005395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21691464">
<a name="21691464"></a>Patka J, Wu DT, Abraham P, Sobel RM. Randomized controlled trial of ondansetron vs. prochlorperazine in adults in the emergency department. <i>West J Emerg Med.</i> 2011;12(1):1-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/21691464/pubmed" id="21691464" target="_blank">21691464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8969995">
<a name="8969995"></a>Pesola GR, Quinto C. Prochlorperazine-induced neuroleptic malignant syndrome. <i>J Emerg Med</i>. 1996;14(6):727-729. doi:10.1016/s0736-4679(96)00186-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/8969995/pubmed" id="8969995" target="_blank">8969995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27423483">
<a name="27423483"></a>Pileggi DJ, Cook AM. Neuroleptic malignant syndrome. <i>Ann Pharmacother</i>. 2016;50(11):973-981. doi:10.1177/1060028016657553<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/27423483/pubmed" id="27423483" target="_blank">27423483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-pms-Prochlorperazine.2013.01">
<a name="pms-Prochlorperazine.2013.01"></a>pms-Prochlorperazine [product monograph]. Montreal, Quebec, Canada: Pharmascience; January 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19156348">
<a name="19156348"></a>Pouwels S, van Staa TP, Egberts AC, Leufkens HG, Cooper C, de Vries F. Antipsychotic use and the risk of hip/femur fracture: a population-based case-control study. <i>Osteoporos Int</i>. 2009;20(9):1499-1506. doi:10.1007/s00198-008-0826-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/19156348/pubmed" id="19156348" target="_blank">19156348</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Prochlorperazine.2013.11">
<a name="Prochlorperazine.2013.11"></a>Prochlorperazine edisylate injection [prescribing information]. Eatontown, NJ: Heritage Pharmaceuticals Inc; November 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Prochlorperazine.1">
<a name="Prochlorperazine.1"></a>Prochlorperazine edisylate injection [prescribing information]. Lehi, UT: Civica, Inc; September 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Prochlorperazine.2019.09">
<a name="Prochlorperazine.2019.09"></a>Prochlorperazine edisylate injection, USP [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; September 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Prochlorperazine.2016.11">
<a name="Prochlorperazine.2016.11"></a>Prochlorperazine tablet [prescribing information]. Pennington, NJ: Zydus Pharmaceuticals (USA) Inc; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Prochlorperazine.2013.10">
<a name="Prochlorperazine.2013.10"></a>Prochlorperazine [prescribing information]. Boucherville, Quebec, Canada: Sandoz Canada Inc.; October 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27779780">
<a name="27779780"></a>Savica R, Grossardt BR, Bower JH, Ahlskog JE, Mielke MM, Rocca WA. Incidence and time trends of drug-induced parkinsonism: A 30-year population-based study. <i>Mov Disord</i>. 2017;32(2):227-234. doi:10.1002/mds.26839<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/27779780/pubmed" id="27779780" target="_blank">27779780</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10216114">
<a name="10216114"></a>Selim K, Kaplowitz N. Hepatotoxicity of psychotropic drugs. <i>Hepatology</i>. 1999;29(5):1347-1351. doi:10.1002/hep.510290535<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/10216114/pubmed" id="10216114" target="_blank">10216114</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sevarino.2021">
<a name="Sevarino.2021"></a>Sevarino KA. Opioid withdrawal in adults: clinical manifestations, course, assessment, and diagnosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 22, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sharman.2019">
<a name="Sharman.2019"></a>Sharman T. A fatal case of prochlorperazine-induced neuroleptic malignant syndrome: a case report and literature review. <i>American Journal of Medical Case Reports</i>. 2019;7(10):253-259. http://www.sciepub.com/AJMCR/abstract/10791
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27176905">
<a name="27176905"></a>Sheridan DC, Laurie A, Pacheco S, et al. Relative effectiveness of dopamine antagonists for pediatric migraine in the emergency department. <i>Pediatr Emerg Care</i>. 2018;34(3):165-168. doi:10.1097/PEC.0000000000000718<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/27176905/pubmed" id="27176905" target="_blank">27176905</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28721057">
<a name="28721057"></a>Solmi M, Murru A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. <i>Ther Clin Risk Manag</i>. 2017;13:757-777. doi:10.2147/TCRM.S117321<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/28721057/pubmed" id="28721057" target="_blank">28721057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1980611">
<a name="1980611"></a>Strauss ME, Reynolds KS, Jayaram G, Tune LE. Effects of anticholinergic medication on memory in schizophrenia. <i>Schizophr Res</i>. 1990;3(2):127-129. doi:10.1016/0920-9964(90)90045-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/1980611/pubmed" id="1980611" target="_blank">1980611</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1679950">
<a name="1679950"></a>Sweeney JA, Keilp JG, Haas GL, Hill J, Weiden PJ. Relationships between medication treatments and neuropsychological test performance in schizophrenia. <i>Psychiatry Res</i>. 1991;37(3):297-308. doi:10.1016/0165-1781(91)90065-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/1679950/pubmed" id="1679950" target="_blank">1679950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12764341">
<a name="12764341"></a>Tanen DA, Miller S, French T, Riffenburgh RH. Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial. <i>Ann Emerg Med</i>. 2003;41(6):847-853. doi: 10.1067/mem.2003.195.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/12764341/pubmed" id="12764341" target="_blank">12764341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3828192">
<a name="3828192"></a>Taylor WB, Bateman DN. Preliminary studies of the pharmacokinetics and pharmacodynamics of prochlorperazine in healthy volunteers. <i>Br J Clin Pharmacol.</i> 1987;23(2):137-142. doi:10.1111/j.1365-2125.1987.tb03021.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/3828192/pubmed" id="3828192" target="_blank">3828192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19150192">
<a name="19150192"></a>Trottier ED, Bailey B, Dauphin-Pierre S, Gravel J. Clinical outcomes of children treated with intravenous prochlorperazine for migraine in a pediatric emergency department. <i>J Emerg Med</i>. 2010;39(2):166-173. doi:10.1016/j.jemermed.2008.08.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/19150192/pubmed" id="19150192" target="_blank">19150192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10473482">
<a name="10473482"></a>van Harten PN, Hoek HW, Kahn RS. Acute dystonia induced by drug treatment. <i>BMJ</i>. 1999;319(7210):623-626. doi:10.1136/bmj.319.7210.623<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/10473482/pubmed" id="10473482" target="_blank">10473482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29061777">
<a name="29061777"></a>Varga B, Csonka Á, Csonka A, Molnár J, Amaral L, Spengler G. Possible biological and clinical applications of phenothiazines. <i>Anticancer Res</i>. 2017;37(11):5983-5993. doi:10.21873/anticanres.12045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/29061777/pubmed" id="29061777" target="_blank">29061777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11239274">
<a name="11239274"></a>Vinson DR. Frequency of adverse reactions to prochlorperazine in the ED: a response. <i>Am J Emerg Med</i>. 2001;19(2):175. doi:10.1053/ajem.2001.21312<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/11239274/pubmed" id="11239274" target="_blank">11239274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30027457">
<a name="30027457"></a>Ward KM, Citrome L. Antipsychotic-related movement disorders: Drug-induced parkinsonism vs. tardive dyskinesia-key differences in pathophysiology and clinical management. <i>Neurol Ther</i>. 2018;7(2):233-248. doi:10.1007/s40120-018-0105-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/30027457/pubmed" id="30027457" target="_blank">30027457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6021058">
<a name="6021058"></a>Warnes H, Lehmann HE, Ban TA. Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases. <i>Can Med Assoc J</i>. 1967;96(15):1112-1113.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/6021058/pubmed" id="6021058" target="_blank">6021058</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32638172">
<a name="32638172"></a>Werner K, Qaiser S, Kabbouche M, Murphy B, Maconochie I, Hershey AD. Intravenous migraine treatment in children and adolescents. <i>Curr Pain Headache Rep</i>. 2020;24(8):45. doi:10.1007/s11916-020-00867-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/32638172/pubmed" id="32638172" target="_blank">32638172</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26573884">
<a name="26573884"></a>Wijemanne S, Jankovic J, Evans RW. Movement disorders from the use of metoclopramide and other antiemetics in the treatment of migraine. <i>Headache</i>. 2016;56(1):153-161. doi:10.1111/head.12712 Erratum in: <i>Headache</i>. 2016;56(3):616.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/26573884/pubmed" id="26573884" target="_blank">26573884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18071091">
<a name="18071091"></a>Wright MT. Antiemetics, akathisia, and pregnancy. <i>Psychosomatics</i>. 2007;48(6):461-466. doi:10.1176/appi.psy.48.6.461<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prochlorperazine-drug-information/abstract-text/18071091/pubmed" id="18071091" target="_blank">18071091</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9816 Version 579.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
